Cancer clinical trial diversity is poor, which matters because of different treatment responses. Solutions are vital to improve trials.

Half of all EU clinical trials are currently running behind schedule due to problems with new regulations for diagnostic medical devices.

A CMO is responsible for compound development success, so building awareness proactively and compliantly is critical for clinical trials.